Trial Profile
A Randomized, Placebo-controlled, Double Blind Phase II/III Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Conestat alfa (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Sponsors Pharming Group NV
- 03 Sep 2014 New trial record